# Phase 2 Trial of Gemcitabine vs S-1 vs Gemcitabine Plus Nab-paclitaxel as Adjuvant Chemotherapy of Post-operative Pancreatic Cancer Patients

> **NCT03278015** · PHASE2 · UNKNOWN · sponsor: **Chinese PLA General Hospital** · enrollment: 90 (estimated)

## Conditions studied

- Cancer of Pancreas

## Interventions

- **DRUG:** Nab-paclitaxel plus Gemcitabine
- **DRUG:** Gemcitabine monotherapy
- **DRUG:** S-1 monotherapy

## Key facts

- **NCT ID:** NCT03278015
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-10-01
- **Primary completion:** 2018-03-31
- **Final completion:** 2018-09-30
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2017-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03278015

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03278015, "Phase 2 Trial of Gemcitabine vs S-1 vs Gemcitabine Plus Nab-paclitaxel as Adjuvant Chemotherapy of Post-operative Pancreatic Cancer Patients". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03278015. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*